Loading stock data…
TAK
$16.36-0.10 (-0.61%)
Market ClosedLast close May 11
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Takeda Pharmaceutical Company Limited in the Healthcare sector is trading at $16.36. The stock is currently 13% below its 52-week high of $18.90, remaining 3.3% above its 200-day moving average. Technical signals show neutral RSI of 32 and bullish MACD crossover, explaining why TAK maintains its current momentum and trend strength. The Whystock Score of 75/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.36
Potential Downside
75.7%
Whystock Fair Value$3.98
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare di...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$52.44B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
75.45
Beta
Defensive asset. Lower volatility than the S&P 500.
0.13
Div Yield
Strong income play. Yield provides a meaningful total return floor.
398.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
1.79%
Volume
Today's trading volume
4.92M
Recent News
Takeda Pharmaceutical (TSE:4502) Valuation Check After Recent Share Price Pullback
Recent share performance and business snapshot Takeda Pharmaceutical (TSE:4502) has recently been on investors’ radar after a period in which the stock fell around 10% over the past month and about 7% over the past 3 months. The company reports annual revenue of ¥4,464,578 and net income of ¥112,926, with both figures showing positive annual growth. The stock’s total return is positive over the past year, 3 years, and 5 years. Takeda generates revenue primarily from pharmaceutical products,...
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects
Denali narrows its Q1 loss and gains FDA approval for Avlayah, the first new Hunter syndrome treatment option in nearly 20 years.
Will the Label Expansion of Asceniv Boost ADMA's Top-Line Growth?
ADMA stock in focus after FDA expands Asceniv's label to younger patients, boosting market reach and growth outlook amid rising demand.
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights
In early May 2026, Takeda informed Denali Therapeutics that it would terminate their collaboration on developing and commercializing DNL593 for business reasons unrelated to the drug’s efficacy or safety, returning full control of the program and its intellectual property to Denali. This shift hands Denali sole ownership of a key neurodegenerative asset built on its TransportVehicle technology, potentially altering how it prioritizes partnerships and internal development across its...
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?
Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the best Japanese stocks to buy right now. On April 6, Denali Therapeutics said Takeda Pharmaceutical Company Limited (NYSE:TAK) is ending its collaboration on DNL 593. The two companies were working on developing the investigational therapy for frontotemporal dementia caused by granulin gene mutations. The candidate drug […]